Last 667.90 INR
Change Today -10.00 / -1.48%
Volume 445.8K
ARBP On Other Exchanges
Symbol
Exchange
Natl India
As of 12:06 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

aurobindo pharma ltd (ARBP) Snapshot

Open
665.25
Previous Close
677.90
Day High
674.00
Day Low
658.35
52 Week High
07/8/14 - 787.30
52 Week Low
08/6/13 - 138.35
Market Cap
194.8B
Average Volume 10 Days
1.2M
EPS TTM
40.23
Shares Outstanding
291.5M
EX-Date
07/30/14
P/E TM
16.6x
Dividend
--
Dividend Yield
0.44%
Current Stock Chart for AUROBINDO PHARMA LTD (ARBP)

Related News

No related news articles were found.

aurobindo pharma ltd (ARBP) Related Businessweek News

No Related Businessweek News Found

aurobindo pharma ltd (ARBP) Details

Aurobindo Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients and finished dosage formulations in India, the United States, Europe, and internationally. The company offers generics formulations primarily in the therapeutic areas of CVS, central nervous system, antibacterial, carbapenems, ophthalmics, oral contraceptives, gastroenterological, NSAIDS, anti-fungal, anti-emetics, anti-virals, anti-diabetics, anti-allergic, antibiotics, and anti-retroviral. The company was founded in 1986 and is headquartered in Hyderabad, India.

Founded in 1986

aurobindo pharma ltd (ARBP) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 7.9M
Whole Time Director and Director of Aurobindo...
Total Annual Compensation: 4.7M
Vice Chairman, Member of Shareholders/Investo...
Total Annual Compensation: 4.7M
Whole Time Director and Member of Shareholder...
Total Annual Compensation: 4.7M
Compensation as of Fiscal Year 2013.

aurobindo pharma ltd (ARBP) Key Developments

Seven Companies Sign Sub-Licensing Agreements with Medicines Patent Pool

Seven subcontracts have been signed licensing agreements with the Switzerland-based Medicines Patent Pool (MPP) to manufacture two antiretroviral drugs. The agreements involve Aurobindo, Emcure (both India), and Desano (China) manufacturing a generic version of Bristol Myers Squibb (BMS, US)'s atazanavir. The manufacturers, including Cipla, Laurus Labs, Micro Labs (all three India), and Mylan (US), have also signed agreements to manufacture ViiV Healthcare (UK)'s dolutegravir. BMS added atazanavir to the MPP in December 2013 and ViiV Healthcare included dolutegravir in the pool in April.

Aurobindo Pharma Limited Announces Chief Financial Officer Changes, Effective July 1, 2014

Aurobindo Pharma Limited has informed that Mr. Sudhir B Singhi, Chief Financial Officer (CFO) of the company has relinquished his duties with effect from 1st July 2014 due to his personal reasons. Mr. Santhanam Subramanian has been appointed as CFO of the Company with effect from 1st July 2014. Mr. Subramanian, a Chartered Accountant, Cost Accountant and Company Secretary has around 30 years of experience and in the past associated with reputed companies in senior positions. He has been with Aurobindo since November, 2013. Mr. Singhi will be relocated to Mumbai as Corporate Financial Advisor and will assist the company in its strategic finance function.

Bristol-Myers Drags Aurobindo and Aurobindo Pharma USA Inc. to US Court

Bristol-Myers Squibb has dragged Aurobindo and its Aurobindo Pharma USA Inc. to the US District Court of New Jersey for alleged patent infringement of its anti-HIV drug 'Reyataz'. In its plea, BMS said legal action has been initiated against Aurobindo for infringement of patent no. 6,087,383 and asked the local American court to with hold approval to manufacture and market a generic version of BMS's Reyataz before the expiration of its patent on December 21, 2018. Bristol-Myers Squibb legal action follows an Abbreviated New Drug Application (ANDA) No 204806 filed by Aurobindo Pharma Ltd. with the US Food and Drug Administration (USFDA) for approval to manufacture and market a generic version of BMS's Reyataz drug product. BMS had clocked sales of $394 million from Reyataz in its fourth quarter ended December 31, 2014. Seeking relief from the US court, BMS stated that damages or other monetary relief must be granted to the company if Aurobindo engages in the commercial manufacture, use, sale of its generic product prior to expiration of the '383 patent. BMS further added that it will be irreparably harmed if Aurobindo's infringement is not enjoined by the court.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARBP:IN 667.90 INR -10.00

ARBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 465.00 INR -0.65
Cipla Ltd/India 444.95 INR +4.00
Divi's Laboratories Ltd 1,471 INR -1.25
Dr Reddy's Laboratories Ltd 2,779 INR +9.50
Ranbaxy Laboratories Ltd 582.10 INR -8.15
View Industry Companies
 

Industry Analysis

ARBP

Industry Average

Valuation ARBP Industry Range
Price/Earnings 16.9x
Price/Sales 2.5x
Price/Book 5.3x
Price/Cash Flow 13.3x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUROBINDO PHARMA LTD, please visit www.aurobindo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.